AIM Historical Cash Flow
| AIM Stock | USD 8.40 0.01 0.12% |
Analysis of AIM ImmunoTech cash flow over time is an excellent tool to project AIM ImmunoTech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 175.9 K or Begin Period Cash Flow of 9.9 M as it is a great indicator of AIM ImmunoTech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining AIM ImmunoTech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AIM ImmunoTech is a good buy for the upcoming year.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. About AIM Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in AIM balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which AIM's non-liquid assets can be easily converted into cash.
AIM ImmunoTech Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from AIM ImmunoTech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into AIM ImmunoTech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.At this time, AIM ImmunoTech's Change To Inventory is very stable compared to the past year. As of the 27th of July 2025, Stock Based Compensation is likely to grow to about 696.4 K, while Free Cash Flow is likely to drop (15.7 M).
AIM ImmunoTech cash flow statement Correlations
Click cells to compare fundamentals
AIM ImmunoTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AIM ImmunoTech cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 37.0M | (6.4M) | (5.0M) | (21.6M) | (3.7M) | (3.6M) | |
| Free Cash Flow | (11.0M) | (14.6M) | (16.4M) | (21.9M) | (14.9M) | (15.7M) | |
| Change In Working Capital | 605K | 895K | 966K | 1.1M | 296K | 175.9K | |
| Begin Period Cash Flow | 1.5M | 38.5M | 32.1M | 27.1M | 5.4M | 9.9M | |
| Total Cashflows From Investing Activities | (9.2M) | (631K) | 11.0M | (832K) | 4.7M | 4.9M | |
| Other Cashflows From Financing Activities | 61.2M | 13.0M | 11.0M | 485K | 3.3M | 3.3M | |
| Depreciation | 733K | 805K | 256K | 238K | 246K | 233.7K | |
| Other Non Cash Items | 1.8M | 4.2M | 964K | 310K | 1.2M | 1.3M | |
| Capital Expenditures | 595K | 633K | 271K | 585K | 18K | 17.1K | |
| Total Cash From Operating Activities | (10.4M) | (14.0M) | (16.1M) | (21.3M) | (14.9M) | (15.6M) | |
| Net Income | (14.4M) | (19.1M) | (19.4M) | (29.0M) | (17.3M) | (18.2M) | |
| Total Cash From Financing Activities | 56.6M | 8.2M | 80K | 485K | 6.4M | 12.3M | |
| End Period Cash Flow | 38.5M | 32.1M | 27.1M | 5.4M | 1.7M | 1.6M | |
| Other Cashflows From Investing Activities | (573K) | (347K) | 11.1M | (585K) | (631K) | (599.5K) | |
| Stock Based Compensation | 1.0M | 1.6M | 954K | 243K | 686K | 696.4K | |
| Change To Account Receivables | 40K | 34K | (35K) | 492K | 1.2M | 1.2M | |
| Investments | (9.2M) | (631K) | 11.0M | (832K) | 4.7M | 4.9M | |
| Issuance Of Capital Stock | 61.2M | 13.0M | 80K | 485K | 892K | 847.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (24.00) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.